What Explains the 3.41% Premarket Decline for Picard Medical (NYSEAMERICAN:PMI)?

Vinay Lochav

09 October 2026 11:46 PM AEDT

What Explains the 3.41% Premarket Decline for Picard Medical (NYSEAMERICAN:PMI)?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Takeaways

Picard Medical (NYSEAMERICAN:PMI) declined 3.41% in premarket activity on October 9, 2026 on a displayed price of USD 9.68 and a Market Value of roughly USD 23 million, with a relative strength index of 72.3, an overbought reading.
The screener tags share issuance, but no offering or issuance disclosure was located for October 8 or 9; the company stated on August 19 it is evaluating additional financing opportunities.
Second-quarter 2026 Revenue increased 39% to approximately USD 3.0 million, gross Margin turned favorable at approximately 20.9%, and net loss narrowed 16% to approximately USD 5.7 million, per the issuer statement.
A 1-for-50 reverse split took effect on July 31, 2026, and NYSE American accepted the business's listing compliance plan in July, a sign the stock needed to lift its price.

Factors Behind Picard Medical’s Share-Price Move

Picard Medical (NYSEAMERICAN:PMI) was indicated to be down 3.41% in the October 9, 2026 premarket session on the screener, on a displayed price of USD 9.68 and pre-market Volume of 497 shares. The screener tags the catalyst as share issuance, but a search located no issuer statement or filing about an offering or issuance dated October 8 or 9, so that label has not been independently confirmed. The quoted price is the October 8 close, when the shares moved higher 3.31%, and a relative strength index of 72.3 indicates an overbought reading, which makes a pullback plausible, an inference. Trading has also been halted for Volatility several times in latest weeks, as listed on a market-data page.

Growth, Reverse Split and Funding Needs

Picard Medical makes the SynCardia total artificial heart for patients with advanced heart failure and is based in Tucson, Arizona. In the second quarter of 2026 revenue increased 39% to approximately USD 3.0 million, mainly from higher United States sales, and first-half revenue increased 50% to approximately USD 4.1 million. Gross margin was approximately 20.9% against a gross loss a year earlier. Net loss narrowed to approximately USD 5.7 million for the quarter but widened to approximately USD 13.3 million for the half. The issuer completed a 1-for-50 reverse split on July 31, leaving approximately 2.34 million shares, and stated it is evaluating additional financing.

Principal Risks and Upcoming Developments

A listed Business losing approximately USD 13.3 million in six months on revenue of USD 4.1 million will probably need to issue shares, and with only approximately 2.34 million shares outstanding, even a small offering can be substantial relative to the float. Picard Medical (NYSEAMERICAN:PMI) also is contingent on a single product line, regulatory approvals for new devices and a long development path for the Emperor total artificial heart. Its Leadership changed in June, when the chief executive stepped down. Investors may wish to follow any offering disclosure, cash disclosures, which the statement did not provide, and listing compliance updates. A premarket decline on 497 shares may reverse at the open, so the figure is only a snapshot of one early session.

Current Assessment

Picard Medical (NYSEAMERICAN:PMI) is trading lower in premarket, but the screener's share issuance tag could not be verified, so the cause is unconfirmed. The verified backdrop is fast growth in revenue from a small base, narrowing quarterly losses, a July reverse split and an explicit need for more financing. The available evidence, viewed as a whole, indicates that a small, overbought stock is fading on thin volume while dilution risk remains. The next items to monitor are any financing disclosure and the next quarterly report.

FAQs

Q: What could explain Picard Medical falling 3.41% premarket?

A: The cause is unconfirmed. The screener tags share issuance, but no disclosure was identified. Picard Medical (NYSEAMERICAN:PMI) was indicated to be down 3.41% on 497 shares and had an overbought reading of 72.3.

Q: How did Picard Medical report in August?

A: Second-quarter revenue increased 39% to approximately USD 3.0 million, gross margin was approximately 20.9% and net loss narrowed to approximately USD 5.7 million. Picard Medical (NYSEAMERICAN:PMI) also stated it is evaluating additional financing.

Q: What did the reverse split do?

A: A 1-for-50 reverse split took effect on July 31, 2026, leaving approximately 2.34 million shares. It lifts the quoted share price mechanically but does not change value, and Picard Medical (NYSEAMERICAN:PMI) still needs listing compliance.

Q: Which risks deserve the closest attention?

A: Dilution from further financing, losses against small revenue, single-product concentration and thin trading. Picard Medical (NYSEAMERICAN:PMI) should be evaluated against filings, and this material is not a recommendation to buy or sell.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.